misbrand

(redirected from misbranding)
Also found in: Medical, Legal.

mis·brand

 (mĭs-brănd′)
tr.v. mis·brand·ed, mis·brand·ing, mis·brands
To brand or label incorrectly, especially in order to mislead or defraud.

misbrand

(ˌmɪsˈbrænd)
vb (tr)
(Marketing) to brand or label incorrectly or misleadingly
Mentioned in ?
References in periodicals archive ?
a Buda, Texas establishment, is recalling approximately 167 pounds of frozen beef patty and gravy products due to misbranding and undeclared allergens, the U.
Raid was conducted on the complaints of misbranding and misleading by the agency.
The owner of a Hauppauge-based vitamin supplement company was sentenced Thursday for misbranding products, falsely claiming to treat or cure several diseases, authorities said.
Trigg said that the clearance means that the product meets the appropriate provisions of the Federal Food, Drug and Cosmetics Act for good manufacturing practice, labeling and prohibitions against misbranding and adulteration.
4) The FDCA prohibited misbranding food and beverages using false or misleading labels to further this goal.
In the Caronia case, the court addressed the FDA's misbranding theory in a muddled way, leaving some uncertainty about the application of its decision in other cases.
The Department of Justice filed a complaint on July 31 alleging that three Wisconsin companies that manufacture dietary supplements were not complying with FDA's current good manufacturing practices and were misbranding their products.
cases of adulteration, misbranding, mislabeling, false advertising and violation of the intellectual property and food safety laws.
The Health Ministry is now registering cases and initiating prosecutions against food product manufacturers involved in alleged adulteration and misbranding.
As reported by The Wall Street Journal, the FDA said that it did "not believe that the Caronia decision will significantly affect the agency's enforcement of the drug misbranding provisions" of the FDCA.
19) Section II reviews representative cases in which the Department of Justice (DOJ) claimed a violation of the FDCA misbranding provisions in the context of scientific exchange.
J&J's Janssen unit will plead guilty to a misdemeanor criminal charge over misbranding Risperdal for uses not approved by the Food and Drug Administration, including treating elderly patients with dementia.